(P-1064) Safety, Tolerability, and Pharmacokinetics of Rifaquizone for Injection in Healthy Participants in China: A Single-center, Double-blind, Randomized, Placebo-controlled, Phase 1 Bridge Study

Friday, October 18, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

Xiaojie Wu, PhD

Deputy Director of Clinical Pharmacology Research Center
Clinical Pharmacology Research Center, Huanshan Hospital
Shanghai, Shanghai, China (People's Republic)

JZ

Jing Zhang, Doctor of Medicine

Huashan Hospital, Fudan University
Shanghai, Shanghai, China
QW

Qiong Wei, Bachelor

Clinical Pharmacology Research Center, Huanshan Hospital
Shanghai, Shanghai, China
Nanyang Li, Master of Medicine (she/her/hers)

Shanghai
Huashan Hospital, Fudan University
Shanghai, Shanghai, China (People's Republic)
SP

Sung Min Park, PhD

Clinical Pharmacology Modeling and Simulation, Allucent
Cary, North Carolina, United States
NS

Navaldeep Singh, PharmaD

Clinical Pharmacology Modeling and Simulation, Allucent
Cary, North Carolina, United States
Jing Chen, Master of Science (she/her/hers)

VP Clinical Operation
TenNor Therapeutics （Suzhou） Ltd
Suzhou, Jiangsu, China (People's Republic)
CA

Changlin Ai, Master of Medicine

TenNor Therapeutics (Suzhou) Ltd
Suzhou, Jiangsu, China
GG

Guozhu Geng, MD

TenNor Therapeutics (Suzhou) Ltd
Suzhou, Jiangsu, China
QZ

Quan Zhang, Bachelor

TenNor Therapeutics (Suzhou) Ltd
Suzhou, Jiangsu, China
Zhenkun Ma, PhD (he/him/his)

CEO
TenNor Therapeutics
Suzhou Industrial Park, Jiangsu, China (People's Republic)